Deville S.,University Paris Diderot |
Carneaux E.,University Paris Diderot |
Bertrand F.,University Paris Diderot |
Cauchard S.,Laboratoire Of Pathologie Equine Of Dozule |
And 2 more authors.
Procedia in Vaccinology | Year: 2011
Companion animals are sensitive species able to strongly react to vaccine. Compared to farmanimals, owner' s sensibility to vaccine safety is exacerbated due to emotional links between animal and owner. Adjuvant selection during vaccine development is a key parameter driving vaccine safety and efficacy profile. Our studies demonstrated the ability to use Montanide™ PetGel A (polymeric adjuvant manufactured under GMP rules) in cat, dog and horse vaccines. Adjuvants performances were highlighted by local and general safety parameters but also through vaccine efficacy to trigger a protective immune response against the pathogen. Three trials were performed to validate Montanide™ PetGel A compatibility with cats, dogs and horses vaccine models. Experimental vaccines were formulated using different antigens according to the animal: inactivated Rhodococcus equi (horse), purified ovalbumin (cat) Leptospira Icterohaemorrhagiae (dogs). In all trials, safety was followed through behavior and temperature measurement. Furthermore, in dog and cat models, histology studies were performed to assess the local reaction in the injection site. A kineticofblood sampling was performed in all trials. Antigen specific ELISAwas used to assess the immune response induced. In cat and dog trials, aluminiumbased formulation were used as benchmark for Montanide™ formulationwhile in horse we compare Montanide™ PetGel Abased vaccine to an already published internal reference. Safety performances ofMontanide™ Pet GelA were superior to aluminium based vaccines in dogs and cats. Transient oedemas were observed in horse vaccine model after each vaccine injection, nevertheless, no impact on the animal behaviorwas observed. The antibodies production induced by Montanide™ PetGel Abased vaccineswas higher than aluminiumbased vaccines or internal reference. Montanide™ PetGel A can be used associated with a wide range ofantigenic media and recommended to be used as adjuvant for sensitive animal' s vaccines. © 2011. Source
Duquesne F.,Laboratoire Of Pathologie Equine Of Dozule |
Hebert L.,Laboratoire Of Pathologie Equine Of Dozule |
Sevin C.,Laboratoire Of Pathologie Equine Of Dozule |
Breuil M.-F.,Laboratoire Of Pathologie Equine Of Dozule |
And 3 more authors.
FEMS Microbiology Letters | Year: 2010
To characterize the potential epidemiological relationship between the origin of Rhodococcus equi strains and the type of their virulence plasmids, we performed a comparative analysis of virulence plasmid types encountered in 96 R. equi strains isolated from (1) autopsied horses, (2) organic samples (horse faeces, manure and straw) and (3) environmental samples. Our results revealed no clear epidemiological link between virulence plasmid type and the origin of R. equi strains isolated from horse-related environments. To understand this result, we determined the nucleotide sequence of the second most frequently isolated virulence plasmid type: a 87-kb type I (pVAPA116) plasmid and compared it with the previously sequenced (and most commonly encountered) 85-kb type I (pVAPA1037) plasmid. Our results show that the divergence between these two plasmids is mainly due to the presence of three allelic exchange loci, resulting in the deletion of two genes and the insertion of three genes in pVAPA116 compared with pVAPA1037. In conclusion, it appears that the divergence between the two sequenced rhodococcal virulence plasmids is not associated with the vap pathogenicity island and may result from an evolutionary process driven by a mobility-related invertase/resolvase invA-like gene. © 2010 Federation of European Microbiological Societies. Source